InvestorsHub Logo
Followers 233
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Re: Iamastockgenius post# 5257

Sunday, 04/28/2013 9:05:24 AM

Sunday, April 28, 2013 9:05:24 AM

Post# of 429056
Genius
Normally generics want to be the first to file, but because exclusivity for Vascepa is protected a in a many ways we could see a large generic sign an "early" partnership deal. Especially if BP doesn't make a move soon on M&A.

If generics defeated all Amarin's patents tomorrow they would not be able to under price Amarin in the market, it wouldn't be worth it to even try...and they would just waste attorney fee's. Amarin has a Monopoly on Icosapent;).

Earliy TEVA rumor could hold true for a partnered Anchor launch, Pfizer, Merck, GSK, and AZN would look pretty stupid.

Williams
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News